Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout
Conditions
Interventions
Febuxostat IR
Febuxostat XR
+4 more
Locations
192
United States
Binghamton, Alabama, United States
Birmingham, Alabama, United States
Huntsville, Alabama, United States
Gilbert, Arizona, United States
Glendale, Arizona, United States
Phoenix, Arizona, United States
Start Date
April 1, 2014
Primary Completion Date
November 1, 2015
Completion Date
November 1, 2015
Last Updated
November 3, 2016
NCT07089875
NCT07116746
NCT03047369
NCT07002762
NCT07310849
NCT05665699
Lead Sponsor
Takeda
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions